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increase in MACCE, validating the SYNTAX Score as prognostic factor.
Conclusion: In SYNTAX, the heart team concluded that CABG and PCI remain the
only treatment options respectively for 25% and 5% of patients. In those patients not
suitable for PCI surgical results are excellent. Patients not candidates for CABG that
underwent PCI had major co-morbidities but a satisfying outcome at three years.
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of the Five-Year Clinical Outcomes from the SPIRIT III Trial
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Background: The SPIRIT III trial compared the XIENCE V (Abbott Vascular, Santa
Clara, CA) everolimus-eluting stent (EES) to the TAXUS EXPRESS2 (Boston
Scientific, Natick, MA) paclitaxel-eluting stent (PES), demonstrating a statistically
significant reduction in the co-primary endpoint of angiographic in-segment late loss
at 8 months, and non-inferiority in the co-primary endpoint of target vessel failure
[TVF; cardiac death, MI, or target vessel revascularization (TVR)] at 9 months. Long-
term data are required to confirm the late safety and efficacy of the EES.
Methods: SPIRIT III was a prospective, randomized, single-blind, controlled trial that
enrolled 1002 men and women at 65 institutions in the US. Patients were randomized
2:1 to EES (n=669) vs. PES (n=333) and underwent percutaneous coronary
intervention in lesions no more than 28 mm in length with 2.5 - 3.75 mm reference
vessel diameter. Treatment of a maximum of two de novo native coronary artery
lesions, each in a different epicardial vessel was permitted. Daily dual antiplatelet
therapy included a thienopyridine for ≥6 months post-procedure and aspirin through 5
years.
Results: At 4-year follow-up, TVF occurred in 17.3% of EES patients vs. 21.2% of
PES patients (HR[95%CI] = 0.77 [0.57, 1.04], p=0.09), and MACE (cardiac death,
myocardial infarction (MI), or ischemia-driven target lesion revascularization) occurred
in 12.3% vs. 17.4% respectively, (0.66 [0.47, 0.93], p=0.02). The hazard curves
continued to diverge between 1 and 4 years. A trend towards fewer late stent thrombosis
events was observed in EES-treated subjects. The 5-year results will be available for
presentation.
Conclusion: EES compared to PES was associated with significantly improved event-
free survival at 4-years. Outcomes at 5 years, representing the longest available clinical
follow-up to date for the EES stent, will provide further insight into the long-term
safety and efficacy of EES.
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Background: The SPIRIT IV randomized trial, the largest completed trial to compare
two drug-eluting stent platforms, the XIENCE V (Abbott Vascular, Santa Clara, CA)
everolimus-eluting stent [EES] compared to the TAXUS EXPRESS2 (Boston
Scientific, Natick, MA) paclitaxel-eluting stent [PES] demonstrated significantly
reduced rates of target lesion failure (TLF) and ischemia-driven target lesion
revascularization (ID-TLR), with non-inferior rates of composite cardiac death or
target-vessel myocardial infarction (MI) through 2 years follow-up. Treatment with
EES also resulted in a significant reduction in the Academic Research Consortium-
defined rate of definite or probable stent thrombosis, and of any MI. Overall outcomes
through 3 years have not yet been reported.
Methods: In the SPIRIT IV trial, 3,687 patients were prospectively randomized 2:1 to
EES vs. PES. Patients with up to 3 de novo native coronary artery lesions (maximum
2 lesions per epicardial vessel) with length ≤28 mm and reference vessel diameter ≥2.5
mm to ≤4.25 mm were enrolled at 66 U.S. clinical sites, stratified by diabetes and
lesion complexity. To enable accurate assessment of clinical event rates, routine
angiographic follow-up was not performed. The trial was powered to demonstrate
sequential noninferiority and superiority of EES compared to PES for the primary
composite endpoint of TLF at 1 year, consisting of cardiac death, target vessel MI, or
ID-TLR.
Results: Two-year follow-up results have been presented, and 3-year results for all
patients will be available in August 2011. In addition to the overall cohort, results
through 3 years will also be reported in the large subset of patients with diabetes
mellitus (1185 randomized patients), in whom TLF rates between EES and PES were
similar at 1 and 2 years.
Conclusion: The three-year outcomes from the SPIRIT IV randomized trial will
provide important insights into the long-term absolute and relative safety and efficacy
EES and PES.
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Are Adverse Events Following Primary PCI for STEMI More Frequent at US
Sites than Sites Outside the US (OUS)? Three-Year Analysis from the
HORIZONS-AMI Trial
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Background: Previous studies have suggested worse outcomes following primary PCI
at US vs OUS sites, but the reasons are not clear and late follow-up has not been
available.
Methods: HORIZONS-AMI randomized 3,602 STEMI pts at 123 centers in 11
countries to Primary PCI with bivalirudin (Biv) vs UFH + GPI.
Results: US vs OUS pts had more diabetes (14.0% vs 9.4%, p=0.0002), prior MI
(13.8% vs 10.1%, p=0.003), prior CABG (5.5% vs 2.2%, p<0.0001), and renal
insufficiency (20.8% vs 15.3%, p=0.0004), were heavier (84.4 vs 80.0kg, p<0.0001)
and had worse LVEF (<40%) (20.8% vs 12.7%, p<0.0001). OUS pts had higher aspirin
use, more primary PCI and stent use, and fewer CABG. OUS pts were discharged more
often on aspirin, beta blockers, ACEI, and statins. At 3 yrs US sites had higher rates of
mortality, MACE, major bleeding and NACE (Table). After adjusting for baseline risk,
mortality, major bleeding and NACE remained significantly more frequent at US sites.
Biv compared to UFH+GPI reduced NACE to a similar extent at US sites (RR: 0.87
[0.69-1.10]) and OUS sites (RR: 0.91 [0.78-1.06]) (p for interaction = 0.76).
Three Year Event Rates: US versus OUS
Conclusion: US versus OUS pts had a higher baseline risk profile and higher rates of
adverse events and bleeding. Mortality, bleeding and NACE were significantly worse
in US pts after adjusting for baseline risk. The reasons for these differences are not
clear but could be due to unmeasured confounders, differences in the threshold for
event reporting, or valid differences in systems of care and treatment which may impact
outcomes.
TCT-32
Intra-Procedural Thrombotic Events During Percutaneous Coronary
Intervention in Patients with Non ST Elevation Acute Coronary Syndromes are
Associated with Adverse Outcomes:Analysis From the ACUITY Trial
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Background: The outcome of PCI in patients with acute coronary syndromes (ACS)
is conventionally judged by the occurrence of composite major adverse cardiac events
(MACE). How often these events occur following intra-procedural complications
during PCI is unknown, with few prior studies assessing the occurrence and importance
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of intra-procedural thrombotic events (IPTE) on subsequent ischemic events.
Methods: 3428 patients who underwent PCI for non ST-segment elevation ACS in the
ACUITY trial underwent detailed frame-by-frame core lab angiographic analysis. An
IPTE was defined as the development of new or increasing thrombus, abrupt vessel
closure, no reflow, slow reflow, or distal embolization at any time during the procedure.
Results: A total of 121 patients (3.5%) had an IPTE. Patients with IPTE less frequently
had diabetes, hypertension, hyperlipidemia, or previous PCI, and more often had
elevated baseline cardiac biomarkers. Patients with IPTE were less often on a statin,
beta-blocker or angiotensin converting enzyme (ACE) inhibitor. Patients with an IPTE
had higher in-hospital, 30-day and 1-year rates of adjudicated MACE (death, MI, or
unplanned revascularization for ischemia) than patients without IPTE (25.6% vs. 6.3%
in-hospital, 30.6% vs. 9.3% at 30 days, and 37.0% vs. 20.5% at 1 year, p<0.0001 for
each). IPTE was strongly associated with Q-wave MI (in-hospital 6.6% vs. 0.5%, 30-
day 7.5% vs. 0.9%, and 1-year 8.5% vs. 1.5%, p<0.0001 for each), and out of lab
definite/probable stent thrombosis (in-hospital 3.3% vs. 0.5%, p=0.006; 30-day 5.8%
vs. 1.3%, p<0.0001; and 1-year 6.7% vs. 2.0%, p=0.0002). Unplanned
revascularization, target vessel revascularization, and non-CABG major bleeding were
also increased in patients with IPTE, as wasoverall 30-day mortality (3.3% vs. 0.7%,
P=0.002). Bymultivariable analyses, IPTE was independently associated with 30-day
and 1-year composite death/MI, definite/probable stent thrombosis, and composite
MACE.
Conclusion: The occurrence of IPTE in patients treated with PCI for ACS, while
relatively uncommon, is strongly associated with subsequent adverse ischemic
outcomes including death, MI and stent thrombosis.
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Background: In patients with ST-segment elevation myocardial infarction (STEMI),
timely reperfusion with primary percutaneous coronary intervention (PPCI) is the
preferred treatment. However, it remains unclear whether the optimal strategy is
complete revascularization or culprit vessel PPCI only.
Methods: From January 1, 2002 to June 25, 2009 all patients presenting with STEMI
treated with PPCI were identified from the Western Denmark Heart Registry, which
serves a population of 3.0 million. We examined mortality according to the timing of
multi-vessel PCI, i.e., acute procedure, staged procedure during the index
hospitalization, or procedure performed within 60 days after the discharge from the
index hospitalization. We compared mortality among patients with multi-vessel PPCI
with that among patients with single-vessel disease (SVD). The hazard ratio (HR) for
death was estimated using a time-dependent Cox regression model, with time of PCI
for the non-culprit lesion as the time-dependent variable.
Results: The study cohort consisted of 5,944 patients, of whom 4,770 (80%) had SVD
and 1,174 (20%) had multi-vessel PCI (MV-PCI) within 60 days. Among patients with
SVD and those with MV-PCI, one-year mortality was 4.9% (n=235) and 4.4% (n=52),
respectively. Among 354 (30.2%) patients with acute MV-PCI, 194 (16.5%) patients
with MV-PCI during the index hospitalization, and 626 (53.3%) patients with MV-PCI
within 60 days after the index hospitalization, the adjusted HRs for one-year mortality
were 1.53 (95% confidence interval (CI): 1.07-2.18), 0.60 (95% CI: 0.28-1.26), and
0.28 (95% CI: 0.14-0.54), respectively, compared to patients with SVD.
Conclusion: Acute MV-PCI in patients with STEMI was associated with increased
mortality compared to patients with SVD. Patients with multi-vessel diseased staged
for complete revascularization during the index hospitalization or within 60 days of
hospital discharge had mortality comparable to patients with SVD.
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Background: Everolimus-eluting stents (EES) have been shown to improve outcome
compared to paclitaxel-eluting stents (PES) in clinical trials. However, limited data are
available comparing second-generation EES with first-generation paclitaxel- and
sirolimus-eluting stents (SES) in real-life practice.
Methods: Analyses were performed on a pooled population of 3 contemporary
randomized trials in the Netherlands. The XAMI trial compared EES and SES in a
wide range of myocardial infarction (MI) patients. The COMPARE trial and
APPENDIX-AMI trial compared EES and either PES or SES in all-comers.
Results: A total of 3408 patients were randomly assigned to EES (53.0%), SES
(20.5%) or PES (26.5%). The groups were well matched in age and sex. However, the
proportion of interventions for acute MI differed between stents (41.1% in EES, 39.7%
in SES and 23.6% in PES, p<0.001). Furthermore, patients in the PES arm were more
likely to suffer from diabetes and hypertension. The unadjusted one-year outcome
showed a comparable incidence of all-cause death between stents (2.5% in EES, 2.8%
in SES and 1.7% in PES, p=0.300). MI occurred in 1.7% of EES patients compared to
0.9% in SES and 5.3% in PES (p<0.001). Target vessel revascularization (TVR) was
more frequent in PES patients (6.0% vs. 2.9% in EES and 3.8% in SES, p<0.001).
Furthermore, the composite end point of MACE (all-cause death, MI and TVR)
occurred more frequently in the PES group (9.1% vs. 6.2% in EES and 6.9% in SES,
p=0.024). Definite stent thrombosis was seen in 2.0% of PES patients, with rates of
0.3% in EES and 0.5% in SES (p<0.001). After multivariate analysis, use of PES was
found to be a predictor of MACE (OR 1.58, 95% CI 1.16-2.16).
Conclusion: In this pooled analysis of real-life practice trials, unadjusted one-year
outcomes were favorable for EES and SES compared to PES. After correction for
baseline differences, PES implantation was found to be an independent predictor of
MACE.
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Initial Findings from ABSORB EXTEND on the Use of Overlapping
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Background: The safety and performance of the ABSORB™ Bioresorbable Vascular
Scaffold (BVS) System (Abbott Vascular, Santa Clara, CA) has been previously
established in 131 patients from Cohort A and Cohort B of the First-in-Man ABSORB
trial. Following this trial, ABSORB EXTEND was initiated as a global continued
access study (outside of the US) to expand experience with the ABSORB BVS to a
larger population of patients with complex lesions, including patients treated for longer
lesions using planned overlap of the ABSORB BVS. As part of the ABSORB EXTEND
study, a 50 patient imaging sub-study is being conducted with the aim of assessing the
outcomes of planned overlapping ABSORB BVS in the treatment of longer lesions.
Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study
that is planning to enroll up to 1,000 subjects at up to 100 sites. Included are patients
with lesions ≤ 28 mm in length and reference vessel diameter of 2.0 - 3.3 mm (as
assessed by on-line QCA). Treatment of target lesion(s) can be conducted using
planned overlap of two ABSORB BVS of 18mm in length. A subset of up to 50 patients
who receive planned overlapping ABSORB BVS will be assessed using OCT,
angiography, and IVUS both post-procedure and at 2 years, in addition to their regular
clinical follow-up.
Results: This report represents the initial findings from patients who have had
implantation of overlapping ABSORB BVS in ABSORB EXTEND. Preliminary
experience with overlapping ABSORB BVS will be reported based on post-procedure
imaging (QCA and OCT) for those patients who are enrolled in the OCT subgroup.
Furthermore, preliminary clinical outcomes in patients receiving overlapping scaffolds
will be presented.
Conclusion: Clinical and imaging outcomes from the First-in-Man ABSORB trial have
demonstrated the safety and efficacy of the ABSORB BVS in lesions ≤ 14 mm.
Preliminary outcomes in patients receiving overlapping BVS from ABSORB EXTEND
will provide information on the feasibility of longer lesion treatment (≤ 28 mm) using
planned overlap of the ABSORB BVS.
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One-Year Clinical Outcomes and Multivariate Predictors Following XIENCE
V® Everolimus Eluting Coronary Stent System Implantation in Real-World
Clinical Settings
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Background: The XIENCE V USA study is a large, prospective, multicenter, FDA-
required post-approval study designed to examine the safety and effectiveness of the
XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V, Abbott Vascular,
Santa Clara) in real-world clinical settings.
Methods: Clinical events, including stent thrombosis (ST), cardiac death and MI, target
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